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ABSTRACT
Inhalation therapy remains the cornerstone of treatment for bronchial diseases. Despite being 
pharmacologically efficacious, currently available inhaled drugs can have decreased real-life effectiveness 
due to a variety of factors, including poor inhalation technique. Each device type has its own specifications 
regarding the optimal way to use it, in terms of device handling and characteristics of the inhalation 
manoeuvre. Poor inhalation technique is associated with decreased treatment effectiveness. Choosing the 
optimal device, together with proper education, improves inhalation technique, adherence and outcomes 
or effectiveness, but has to be performed regularly and rigorously, including visual checking of the patient’s 
ability to use the inhaler. Some testing devices are also available, as well as various training materials. All 
healthcare professionals caring for the patient can be involved provided that they have also been properly 
trained. To optimise treatment effectiveness, healthcare providers should prescribe inhalation device(s) 
optimised to the patient, accounting for the specific characteristics of each individual, his/her disease, and 
involved healthcare professionals.
Keywords: Asthma, COPD, inhaler, metered-dose inhaler, dry-powder inhaler, technique, effectiveness, 
education.
INTRODUCTION
Asthma and chronic obstructive pulmonary disease 
(COPD) are among the most frequently occurring 
respiratory diseases and represent a major public 
health burden.1,2 They are both pulmonary diseases, 
resulting from interactions between environmental 
exposures and genetic predispositions. The inhaled 
route is crucial for their treatment since it allows 
pharmacological agents (currently, β2-adrenergic 
and anticholinergic bronchodilators and topical 
corticosteroids) to be delivered directly to their 
target receptors while minimising systemic exposure 
and, thus, side-effects.3,4 
Several types of portable inhaler devices are now 
available to administer inhaled drugs, and can be 
classified in several ways. The first classification 
differentiates: (1) propellant-driven pressurised 
metered-dose inhalers (pMDIs), which include 
standard (i.e. non-breath-actuated) devices, which 
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can be used with spacers, and breath-actuated 
pMDIs (BAIs); versus (2) non-propellant-driven dry-
powder inhalers (DPIs), which can be multi-dose 
(with an integrated reservoir) or single-dose (using 
capsules). An alternative classification differentiates 
devices that require accurate coordination between 
triggering and inhalation (i.e. pMDIs without spacers) 
and those that were developed to alleviate the need 
for proper coordination, i.e. spacers, BAIs and DPIs.5 
Among pMDIs, devices delivering HFA-propelled 
extra-fine particles have been developed. These 
devices increase deposition in small airways and 
reduce the influence of errors in coordination and 
inhalation flow.6,7 Nebulisers are not discussed here 
since they are considered as second line devices for 
long-term treatment of asthma and COPD.1,2
The important characteristics of the dose emitted 
include the mass median aerodynamic diameter 
(MMAD) and the fine particle dose (FPD). The 
MMAD provides an understanding of the size of the 
emitted particles, with those <5 µm being the most 
likely to be deposited into the airways. The FPD is 
the amount of particles with a size <5 µm.5
The effectiveness of inhaled treatments is 
influenced by several factors, including: (1) their 
efficacy, i.e. their positive effects when used under 
optimal conditions, directly resulting from their 
pharmacological properties; and, (2) the way they 
are used, i.e. the appropriateness of prescription 
and patients’ adherence and ability to use inhalation 
devices. A systematic review of efficacy studies (i.e. 
randomised controlled trials) performed a decade 
ago did not find significant differences between 
devices.8 Usually, patients were highly trained 
regarding their inhalation technique and those 
who did not demonstrate correct use post-training 
were excluded. Thus, the real-life effectiveness 
of the various available devices is not known and 
could be markedly influenced by the way they are 
used. A systematic review, by Brocklebank et al. 
in 2001, underlined the need for additional 
studies aimed at determining whether some 
differences between devices can be identified in 
terms of effectiveness.9 Some studies have been 
conducted thereafter to address this issue.10,11
Misuse of inhalers will prevent the pharmacological 
agent from reaching its target, resulting in a 
decreased effect.12 The amount of drug depositing 
in the lung depends on three factors: the drug 
formulation, the technical characteristics of the 
device (such as its external and internal design 
and, for DPIs, the resistance to inhalation), and 
the ability of the patient to handle it and inhale 
properly (Figure 1).
Many studies have investigated the frequency 
and consequences of inhaler misuse. Their results 
support the major importance given to inhaler 
technique as a determinant of treatment success. 
However, only few guidelines address the issue of 
inhaler technique in detail.5,13 As a consequence, 
several international groups developed a specific 
interest for research and communication on this 
topic, such as the Asthma Drug Management 
Team (ADMIT) (http://www.admit-online.info/
en/), and the recently established Respiratory 
Effectiveness Group (REG), (http://www.
effectivenessevaluation.org/).
Figure 1. Basic principles in inhalation therapy: factors that influence the effectiveness of inhaled 
medications. MMAD: mass median aerodynamic diameter. Fine/respirable particles: MMAD <5 µm.
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BASIC PRINCIPLES OF INHALER USE 
The following steps of inhaler use are common to 
all devices: (1) device preparation (shaking for some 
pMDIs, adaptation to the spacer when required, 
priming for BAIs and reservoir DPIs, capsule 
insertion for single-dose DPIs); (2) exhalation 
followed by deep inhalation (coordinated with 
device triggering for pMDIs); (3) breath-holding 
(lasting at least 4 seconds); and, finally (4) normal 
breathing  lasting at least 30 seconds before 
repetition of all these manoeuvres when a second 
dose is required. With pMDIs and BAIs, the drug 
formulation is propelled by the pressurised gas 
contained in the cartridge when the device is 
actuated, either manually (pMDIs) or 
automatically when inhalation begins (BAIs). 
Therefore, the main initial driving force 
is propulsion by the pMDI device and, as 
such, the inhalation needs to be slow. In contrast, 
when using DPIs, the only driving force is 
inhalation. The formulation of a DPI is broken up 
(de-aggregated) during the first part of each 
inhalation into particles that have characteristics 
suitable for deposition into the lungs (i.e. a 
diameter of <5 µm). This break-up is caused by 
a turbulent force that is generated inside the DPI 
by the interaction between the patient’s inhalation 
and the resistance of the device.  Each DPI has its 
own resistance ranging from low to high.5  To obtain 
a set inhalation flow with higher resistance, 
the patient needs to use a more forceful initial 
inhalation.14 Hence, compared to a pMDI, the 
inhalation manoeuvre from a DPI needs to be 
forceful, which many translate to ‘as fast as you 
can’. Since the break-up of the dose occurs in the 
first part of the inhalation, the instruction with a 
DPI is ‘forceful from the start’.  Together with the 
intrinsic aerodynamic properties of drug particles, 
this explains why inhalation should preferentially be 
slow with pMDIs (especially to limit oropharyngeal 
impaction), while it has to be fast from the beginning 
with DPIs.15-17 These inhalation manoeuvres are 
required to provide ideal inhalation flows of 30  L/
min for pMDIs and between 30-90 L/min  for DPIs. 
Finally, to ensure good penetration into the lungs, a 
deep inhalation manoeuvre is required and is usually 
defined as lasting at least 4-5 seconds. 
FREQUENCY AND DETERMINANTS OF
INHALER MISUSE 
All studies in this area agree on a high proportion 
of misuse among patients with asthma or COPD, 
even in those who had been exposed to devices for 
long periods.18-22 However, the frequency of misuse 
for each particular type of device varies between 
studies, depending on the studied population and 
Figure 2. Frequency of inhalation errors by device type. Data from three studies.19,20,22
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on the criteria used to define proper technique. 
Figure 2 combines results from some of these 
studies. Altogether, standard pMDIs are definitely 
the devices with the highest proportion of errors, 
but misuse is also frequent with the other types 
of devices; these have been developed to limit 
the impact of poor coordination but still need 
proper preparation, inhalation and breath-holding. 
Preparation errors relate, for example, to improper 
device priming manoeuvres including improper 
device position. Thus, none of the devices currently 
available can be considered as ‘ideal’ in that 
all require some patient skill. As a consequence, 
training is always required to ensure adequate 
patient education about specific handling 
requirements, as well as on the inhalation technique 
per se.5
Some patients appear to be at higher risk of 
poor inhalation technique.22,23 Some risk-factors 
relate directly to the patient, these include: 
extreme ages (i.e. young children and the 
elderly), very severe airflow obstruction, cognitive 
dysfunction, motor handicap of the upper 
extremities, and co-morbidities such as stroke 
etc. In addition, patient preference could be 
associated not only with compliance but also with 
inhalation technique.24 Other risk factors relate 
to the prescription and delivery of the treatment: 
patients who are simultaneously prescribed 
different types of devices (e.g. a pMDI and a DPI)25 
tend to use their devices less appropriately than 
those using a single device type (although some 
controversial data on this topic have been published 
in children),26 and device switching without a 
face-to-face review is associated with worsening 
of asthma control.27 The last group of risk factors 
relates to measures that should accompany the 
prescription: patients are to be trained on the optimal 
way of using their device, and inhalation technique 
has to be checked regularly. Virtually all healthcare 
professionals can be involved in patient training and 
follow-up regarding inhaler technique: primary care 
physicians, lung specialists, pharmacists, nurses, and 
physiotherapists. Since healthcare providers’ skills 
and knowledge of inhalers can also be poor, they 
require training on correct inhaler handling.28
IMPACT OF INHALER MISUSE ON 
TREATMENT EFFECTIVENESS
Clinical consequences of poor inhalation technique 
have been studied mostly in asthma, where it is easier 
to explore links between inhaler use and control. 
Such studies are more difficult in COPD due to the 
very progressive nature of the disease and relatively 
small magnitude of observable treatment effects in 
the short-term.
It has long been known that pMDI misuse decreases 
the amount of drug deposited in the lungs and 
that, in patients with poor coordination, deposition 
can be improved by the use of spacers, BAIs or 
DPIs.29 Corresponding studies used mostly 
scintigraphy with Technetium-radio-labelled 
particles as a means to provide images showing 
the level of deposition in the device, throat, 
lungs, and stomach.30 Others have measured 
blood levels of administered drugs or their 
metabolites, blocking digestive absorption with 
charcoal so that systemic exposure results from 
lung absorption only, which directly correlates with 
lung deposition.31 It has also been demonstrated 
that the magnitude of bronchodilation, obtained 
by β2-agonists, decreases in poor users.32 Finally, 
more recent studies managed to show a link 
between poor inhaler technique and poor asthma 
control.18,33-35 In one of these studies, a “dose-
dependent” relationship was even found between 
the number of errors in pMDI use and the level 
of control (named “instability” at that time).18 
Asthma control was worse in poor pMDI users 
and, among errors in inhalation technique, poor 
coordination had the greatest impact on control. 
More recently, these authors found a triangular 
relationship between control, adherence to 
treatment and inhaler technique.33 Poor inhalation 
technique and poor compliance were both 
independently associated with control, the other risk 
factor for poor control in that study being smoking.
Altogether, these results show that inhalation 
technique should belong to the systematic 
check-list when assessing a patient with insufficient 
asthma control, together with smoking status, 
other environmental exposures (to allergens or 
irritants), body mass index, adherence to treatment, 
associated diseases, or an alternate diagnosis 
(gastro-oesophageal reflux, COPD, hyperventilation 
syndrome, vocal cord dysfunction, congestive 
heart failure, vasculitis, allergic bronchopulmonary 
aspergillosis).36,37 
COMBATTING INHALER MISUSE TO 
IMPROVE TREATMENT EFFECTIVENESS
Three directions can be followed to decrease 
the frequency and consequences of poor 
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inhalation technique: research to improve inhalers, 
training patients and doctors, and individualising 
inhaler choice. 
Developing the ‘Ideal Inhaler’
The ideal inhaler would be user-friendly, delivering 
optimal respirable amounts of drugs irrespective 
of the prescriber and patient’s skills, without any 
need for external supervision and independently 
of environmental conditions. More realistically, it 
should have the characteristics described in Table 
1. To date, none of the currently available inhalers 
can be considered as ‘perfect’ regarding all these 
characteristics. All need some training and regular 
checking of inhalation technique. However, some 
new inhalers try to simplify required manipulation. 
It must also be noted that most devices still 
do not deliver all pharmacological classes of 
respiratory drugs. Thus, the choice of the prescribed 
pharmacological agent restricts (and can be 
restricted by) the number of devices that can 
be proposed. 
Checking and Training
Several observational studies have shown that 
training patients on inhaler use improves not 
only inhalation technique but also adherence to 
treatment and, most importantly, disease 
control.15,33,38,39 Most of these studies are purely 
observational with a ‘before-after’ design, and 
include only patients with asthma. Only a few 
specifically recruited patients with COPD, in 
whom similar improvements were demonstrated.39 
Interestingly, one observational study found that 
control improved only in those patients in whom 
inhaler technique improved following training 
by pharmacists, suggesting that the effect of 
training on control is actually determined by its 
effect on inhaler technique.33 Similar results were 
very recently found in COPD patients.40 However, 
it has also been shown that the effect of training is 
inconstant and sometimes transient.41
Several tools and strategies can be used to provide 
training: visits to health care professionals using 
placebo demonstration devices or the patient’s 
own device, video demonstration of adequate 
and incorrect technique, tele-counselling,42 and 
web-based programs.43 As mentioned above, all 
healthcare professionals should be involved in 
this training process: primary care physicians, 
lung specialists, nurses, physiotherapists, and 
pharmacists. The choice of tools and involved 
professionals often depends on local availability 
and organisation. It is also of utmost importance to 
educate professionals properly in the first place44 
and then repeat training regularly.
In all cases, it must be outlined that providing 
patients with written material (such as brochures 
and leaflets) is not sufficient. A critical step in 
education is the regular observation of the patient 
using his/her inhaler. The other major step is the live 
demonstration of proper technique when necessary, 
followed by repeated observation of the patient’s 
ability to correct his/her technique. Simply asking 
the patient whether he/she has difficulties using his/
her inhaler does not provide reliable information.21
Criteria Device and inhalation technique characteristics
General appearance User-friendly
Priming None 
Coordination between triggering and inhalation Not required
Effect of errors in inhalation technique None 
Dose consistency Perfect, independently of environmental conditions (temperature, humidity etc) and inhalation manoeuvre
Dose counter Present, based on actual inhalation rather than manipulation
Perception of drug delivery Clear perception (but not based on unpleasant sensations such as bad taste)
Feedback
Confirmation that a dose has been inhaled,  
technique used was correct  
Reminder about adherence
Table 1. Theoretical characteristics of the ideal inhaler.
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Table 1. Theoretical characteristics of the ideal inhaler.
Of note, some testing and training devices have 
been developed to help healthcare professionals 
check inhalation technique and train patients.15,41 
They are known to improve inhalation technique, 
but their cost-effectiveness remains unknown at 
present. In addition, no study has investigated the 
effect of training or the most desirable training 
method/tool in situ over a prolonged period of time.
Personalising Device Choice
Patients with asthma or COPD do not all require 
the same treatment, and do not all have the same 
skills and preferences. Therefore, tailoring the 
treatment to each specific patient is of utmost 
importance.3,45-49 Several factors have to be taken 
into account when selecting a specific inhaler 
device for each patient. These factors can be 
categorised in four ways: (1) Patient-related factors, 
including (i) age and ability to inhale consciously, 
handle the device and coordinate the use of the 
device and the inspiratory effort, (ii) patient’s 
preference, (iii) adherence and compliance, 
(iv) language and literacy, and (v) presence of 
comorbidities that could be aggravated by some 
respiratory treatments. (2) Disease-related factors, 
since (i) severe and/or acute airflow obstruction 
may compromise the ability to generate an 
adequate inspiratory flow and (ii) therapeutic 
strategy and indications are not the same for 
asthma and COPD. (3) Device-related factors, 
as the optimal inhalation profile differs between 
pMDIs (slow inspiration is preferable) and DPIs 
(forceful high-flow inhalation is not required, 
with fast acceleration especially for reservoir 
devices). For example, observational comparative 
effectiveness studies suggested that BAIs and 
standard pMDIs (using HFA-propelled extra fine 
particles with a size of approximately 1 µm) could 
improve treatment effectiveness as compared 
to standard metered-dose inhalers,7,8 due to the 
more limited influence of errors in coordination/
inhalation technique on lung deposition with these 
devices.6,7 Finally, (4) Caregiver-related factors, 
accounting for the availability and knowledge 
of professionals involved in information and 
education (general practitioners, specialists, nurses, 
physiotherapists, pharmacists).
In addition, the multiplication of inhalation 
devices and corresponding instructions should 
be avoided since it can be a source of confusion 
for healthcare providers who are not specialised 
in the respiratory area, such as many primary care 
physicians, even though they care for the majority of 
patients with asthma or COPD.
CONCLUSIONS
The inhaled route remains crucial for the treatment 
of bronchial diseases. However, drug deposition 
and subsequent treatment effectiveness are 
highly dependent on inhalation technique, which 
is incorrect in many patients with asthma and 
COPD. Many inhalation devices are available and 
others are currently being developed with the 
aim of simplifying required handling, and thus 
improving treatment safety. Nonetheless, at present, 
proper training and regular checking of inhalation 
technique remain critical to optimise treatment 
effectiveness. Involved healthcare professionals 
have to be adequately trained before providing 
this service. Various educational tools can be 
used including videos, web-based platforms, and 
tele-counselling. Optimising treatment effectiveness 
also requires tailoring the drug-device combination 
chosen for each individual patient, based on 
his/her individual characteristics, the specific disease 
and its severity, the characteristics of devices, and 
the skills of involved healthcare professionals. There 
is a need for long term effectiveness studies to 
identify the training methods/tools that should be 
used for each inhaler.
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